These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1283 related items for PubMed ID: 28209373

  • 1. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E, Joutseno J, Sumelahti ML.
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T.
    J Med Econ; 2016 Mar; 19(4):432-42. PubMed ID: 26707273
    [Abstract] [Full Text] [Related]

  • 3. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Su W, Kansal A, Vicente C, Deniz B, Sarda S.
    J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S, Grimm S, van Hövell P, Freudensprung U, Pellegrini F, Hyde R, Bergmann A, NTD Study Group.
    J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
    [Abstract] [Full Text] [Related]

  • 5. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    Chevalier J, Chamoux C, Hammès F, Chicoye A.
    PLoS One; 2016 Dec; 11(3):e0150703. PubMed ID: 26987055
    [Abstract] [Full Text] [Related]

  • 6. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ, Auguste P, Armoiry X, Maheswaran H, Court R, Madan J, Kan A, Lin S, Counsell C, Patterson J, Rodrigues J, Ciccarelli O, Fraser H, Clarke A.
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.
    Alsaqa'aby MF, Vaidya V, Khreis N, Khairallah TA, Al-Jedai AH.
    Ann Saudi Med; 2017 Sep; 37(6):433-443. PubMed ID: 29229891
    [Abstract] [Full Text] [Related]

  • 8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
    Cochrane Database Syst Rev; 2017 Apr 25; 4(4):CD012200. PubMed ID: 28440858
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.
    Zhang X, Hay JW, Niu X.
    CNS Drugs; 2015 Jan 25; 29(1):71-81. PubMed ID: 25326785
    [Abstract] [Full Text] [Related]

  • 10. Teriflunomide for multiple sclerosis.
    He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD009882. PubMed ID: 23235682
    [Abstract] [Full Text] [Related]

  • 11. Teriflunomide for multiple sclerosis.
    He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.
    Cochrane Database Syst Rev; 2016 Mar 22; 3(3):CD009882. PubMed ID: 27003123
    [Abstract] [Full Text] [Related]

  • 12. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT, Arndt N, Roman C, Geremakis C, Mendoza JP, Su R, Makin C, Avila RL, Vignos MC.
    Mult Scler Relat Disord; 2021 Jun 22; 51():102935. PubMed ID: 33882426
    [Abstract] [Full Text] [Related]

  • 13. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM.
    J Manag Care Pharm; 2009 Sep 22; 15(7):543-55. PubMed ID: 19739877
    [Abstract] [Full Text] [Related]

  • 14. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ, Montgomery SM, Griffiths MJ, Bergvall N, Adlard N.
    J Med Econ; 2015 Sep 22; 18(11):874-85. PubMed ID: 26055952
    [Abstract] [Full Text] [Related]

  • 15. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
    Zagmutt FJ, Carroll CA.
    Int J Neurosci; 2015 Sep 22; 125(11):798-807. PubMed ID: 25387069
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP.
    J Med Econ; 2017 Oct 22; 20(10):1056-1065. PubMed ID: 28703659
    [Abstract] [Full Text] [Related]

  • 17. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C, Aloi JJ.
    Clin Ther; 2015 Apr 01; 37(4):691-715. PubMed ID: 25846320
    [Abstract] [Full Text] [Related]

  • 18. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Dashputre AA, Kamal KM, Pawar G.
    J Manag Care Spec Pharm; 2017 Jun 01; 23(6):666-676. PubMed ID: 28530523
    [Abstract] [Full Text] [Related]

  • 19. Real-life use of oral disease-modifying treatments in Austria.
    Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T, Austrian MS Treatment Registry (AMSTR).
    Acta Neurol Scand; 2019 Jul 01; 140(1):32-39. PubMed ID: 30958901
    [Abstract] [Full Text] [Related]

  • 20. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E, Berger T, Bajer-Kornek B, Deisenhammer F.
    J Med Econ; 2019 Mar 01; 22(3):226-237. PubMed ID: 30522373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.